Clinical trials: Hepotacellular Carcinoma
Hepotacellular Carcinoma
Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention
This study is for patients with early-stage liver cancer who are planning to have surgery. The goal of this research is to see if a personalized treatment plan, guided by a computer model (an artificial intelligence tool), can…
- Trial name
- NCT07282184
- Testing
- Neoadjuvant HAIC + Lenvatinib + PD-1 Inhibitor, Curative Liver Resection, Multimodal AI Risk Stratification
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Tongji Hospital
Cirrhosis, Hepotacellular Carcinoma
The Role of Serum AKR1B10 in Early Warning of Hepatocellular Carcinoma in Cirrhosis Patients
Hepatocellular carcinoma (HCC) is a globally prevalent malignancy. In its characteristic "chronic hepatitis-liver cirrhosis-HCC" progression trilogy, patients with cirrhosis demonstrate a 5-year HCC incidence rate of 3%-5%, yet…
- Trial name
- AKR1B10 (NCT07147335)
- Testing
- serum AKR1B10 levels
- Where
- China
- Volunteers
- 800 people
- Sponsor
- The First Affiliated Hospital of University of South China
Hepotacellular Carcinoma, Cholangiocarcinoma
Hepatobiliary and Pancreatic Tumor Biobank
This study aims to establish a hepatobiliary and pancreatic tumor biobank at the Second Affiliated Hospital of Zhejiang University School of Medicine.
- Conditions
- Hepotacellular Carcinoma, Cholangiocarcinoma, Pancreatic Cancer
- Trial name
- NCT07344116
- Testing
- No Interventions
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine